Bibliography
- BONE RC, BALK RA, CERRA FB et at Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest (1992) 101:1644–1655.
- ANEL R, DELLINGER RP: Sepsis and bacteremia. In: Corith Current Therapy Rake! RE, Bope ET (Eds.), WB Saunders Co. (2001):56–62.
- WEIL MH, MACLEAN CD, FISSEHER MB, SPINK WW: Studies of the circulatory changes in the dog produced by endotoxin from Gram-negative microorganisms. J. Clin. Invest. (1956) 35:1191–1198.
- SWINGLE WW, PFIFFNER JJ: An aqueous extract of the suprarenal cortex which maintains the life of adrenalectomized cats. Science (1930) 71:321–322.
- HARTMAN FA, SCOTT WJM: Protection of adrenalectomized animals against bacterial intoxication by an extract of the adrenal cortex. J. Exp. Med. (1932) 55:63–69.
- ANNANE D, SEBILLE V, TROCHE G et al.: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA (2000) 283:1038–1045.
- ZALOGA GP: Sepsis-induced adrenal deficiency syndrome. Grit. Care Med. (2001) 29:688–690.
- ROBSON HG, CLUFF LE: Experimental pneumococcal and staphylococcal sepsis: the effects of hydrocortisone and phenoxybenzamine upon mortality rate. J. Gun. Invest. (1966) 45:1432.
- FABIAN TC, PATTERSON R: Steroid therapy in septic shock. Survival study in a laboratory model. Am. Surgeon (1982) 48:614–617.
- HINSHAW LB, ARCHER LT, BELLER TODD BK etal.: Survival of primates in lethal septic shock following delayed treatment with steroid. Circ. Shock (1981) 8:291–300.
- HINSHAW LB, BELLER TODD BK, ARCHER LT et at Recovery from lethal Escherichia mlishock in dogs. Surg. CyrrecoL Obstet. (1979) 149:545–553.
- HINSHAW LB, ARCHER LT, BELLER TODD BK etal.: Survival in primates in lethal septic shock following delayed treatment with steroid. Circ. Shock (1981) 8:291–300.
- SCHUMER W: Steroids in the treatment of clinical septic shock. Ann. Surg. (1976) 184:333–341.
- SPRUNG CL, CARALIS PV, MARCIAL EH et al.: The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl. J. Med. (1984) 311:1137–1143.
- BONE RC, FISCHER CJ JR, CLEMMERTP et al.: A controlled trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N ErigL Med. (1987) 317:653–658.
- THE VETERANS ADMINISTRATION SYSTEMIC SEPSIS COOPERATIVE STUDY GROUP: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis, N ErigL J. Med. (1987) 317:659–665.
- LUCE JM, MONTGOMERY AB, MARKS JD etal.: Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am. Rev Respir Dis. (1998) 138:62–68.
- LEFERING R, NEUGEBAUER EAM: Steroid controversy in sepsis and septic shock: A meta-analysis. Grit. Care Med. (1995) 23:1294–1303.
- CRONIN L, COOK DJ, CARLET J etal.:Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Grit. Care Med. (1995) 23:1430–1439.
- CARLET J: Immunological therapy in sepsis: Currently available. Intensive Care Med. (2001) 27:S93–S103.
- LEBEL MH, FEIJI BJ, SYROGAINNOPOLOUS GA et at Dexamethasone therapy for bacterial meningitis: Results of two, double-blind, placebo-controlled trials. N ErigL J. Med. (1988) 319:964–971.
- HOFFMAN SL, PUNJABI NH, KUMALA S et al.: Reduction in mortality in chloramphenicol treated severe typhoid fever by high-dose dexamethasone. N ErigL J. Med. (1984) 310:82–88.
- GAGNON S, BOOTA AM, FISCHL MA etal.: Corticosteroids as adjunctive therapy for Pneumocystic carinii pneumonia in the acquired immunodeficiency syndrome. N ErigL J. Med. (1990) 323:1440–1450.
- MONTANER JS, LAWSON LM, LEVITT M et al.: Corticosteroids prevent early deterioration in patients with moderate severe Pneumocytis carinii pneumonia and the acquired immunodeficiency syndrome. Ann. Intern. Med. (1990) 113:14–20.
- MEDURI GU, HEADLEY ASH, GOLDEN E et al: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. JAMA (1998) 280:159–165.
- BOLLAERT PE, CHARPENTIER C, LEVY S et al.: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Grit. Care Med. (1998) 26:645–650.
- CHAWLA K, KUPFER Y, GOLDMAN I, TESSLER S: Hydrocortisone reverses refractory septic shock. Grit. Care Med. (1999) 27(Suppl):A33
- BRIEGEL J, FOREST H, HALLER M et al.: Stress doses of hydrocortisone reverse hyperdynamic septic shock; A prospective, randomized, double-blind, single-center study. Grit. Care Med. (1999) 27:723–732.
- BRIEGEL J, JOCHUM M, GIPPNER-STEPPERT C, THIEL M: Immunomodulation in septic shock: Hydrocortisone differentially regulates cytokine reponses. j Am. Soc. Nephrol. (2001) 12\(Suppl. 17):570–574.
- ANNANE D: Effects of the combination of hydrocortisone-fludrocortisone on mortality in septic shock. Grit. Care Med. (2000) 28:A46 (Abstract).
- MARIK P, ZALOGA G: Prognostic value of cortisol response in septic shock. (letter; comment). JAMA (2000) 284:308–309.
- MARIK PE, KIMINYO K, OLEXO S et al.: Occult adrenal insufficiency in critically ill patients. An underdiagnosed entity. (abstract) Grit. Care Med. (1999) 27:A141.
- SONI A, PEPPER GM, WYRWINSKI PM et al.: Adrenal insufficiency occurring during septic shock: Incidence, outcome, and relationship to peripheral cytokine levels. Am J. Med. (1995) 98:266–271.
- KERI G, PARAMESWARAN V, RAMACHANDIAN J et at Mechanisms of adrenocortical cell function. Life Sri. (1981) 28:1917–1923.
- ZHU Q, SOLOMON S: Isolation and mode of action of rabbit corticostatin (antiadrenocorticotropin) peptides. Endocrinology (1991) 128:623–629.
- KOO DJ, JACKMAN D, CHAUDRY IH et al.: Adrenal insufficiency during the late stage of polymicrobial sepsis. Grit. Care Med. (2001) 29:618–622.
- FINDLING JW, WATERS VO, RAFF H: The dissociation of renin and aldosterone 1482 during critical illness. J. CM]. Endocrinol. Metabol (1987) 64:592–595.
- CHRISTEFF N, CARLI A, BENASSAYAG C etal.: Relationship between changes in serum estrone levels and outcome in human males with septic shock. Circ. Shock (1992) 36:249–255.
- WHEELER AE BERNANRD GR: Treating patients with severe sepsis. N Engl. J. Med. (1999) 340:207–214.
- DINARELLO CA, GELFAND GA, WOLFF SM: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA (1993) 269(14):1829–1835.
- ROSENBERG RD, AIRD WC: Vascular-bed-specific hemostasis and hypercoagulable states. N Eng1J. Med. (1999) 340:1555–1564.
- ESMON NL, ESMON CT: Protein C and the endothelium. Semir]. Thromb. Hemost. (1988) 14:210–215.
- HERBERT PC, DRUMMOND AJ, SINGER J et al: A simple multiple organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest (1993) 104:230–235.
- GANDO S, NANZAKI S, SASAKI S et al.:Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Grit. Care Med. (1998) 26:2005–2009.
- MESTERS R, HELTERBRAND J, UTTERBACK BG et al.: Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit. Care Med. (2000) 28:2209–2216.
- SCHMIDT-SUPPRIAN M, MURPHY C, WHILE B et al.: Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes. Eur. Cytokine Network (2000) 11:407–413.
- TAYLOR FB JR: Studies on the inflammatroy-coagulant axis in the baboon response to E. Colt. regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor. Frog. Clin. Biol. Res. (1994) 388:175–194.
- LORENTE JA, GARCIA-FRADE LJ, LANDIN L et al: Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest (1993) 103:1536–1542.
- MESTERS RM, MANNUCCI PM, COPPOLA E et al: Factor VIIA and antithrombin III activity during sever sepsis and septic shock in neutropenic patients. Blood (1996) 88:881–886.
- ABRAHAM E: Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Grit. Care Med. (2000) 28(9 Suppl):531–533.
- BLAUHUT B, NECEK S, VINAZZER H et al.: Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb. Res. (1982) 27:271–278.
- FOURRIER F, CHOPIN C, HUART JJ et al.: Double-blind, placebo controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest (1993) 104:882–888.
- BALK RA, BEDROSSIAN C, MCCORMICK L et al: Prospective, double-blind, placebo-controlled trial of ATIII substitution in sepsis (Abstract). Intensive Care Med. (1995) 21\(Suppl. 1):517.
- BAUDO F, CAIMI TM, DE CATALDO E etal.: Antithrombin III replacement therapy in patients with sepsis and/or surgical complications: A controlled, double-blind, randomized, multicenter study. Intensive Care Med. (1998) 24:336–342.
- EISELE B, LAMY M, THUS LG et al: Antithrombin III in patients with severe sepsis: A randomized, placebo-controlled, double-blind, multicenter trial plus a meta-analysis on all randomized placebo-controlled multicenter trials with antithrombin III in severe sepsis. Intensive Care Med. (1998) 24:663–672.
- FOURRIER F, JOURDAIN M, TOURNOYS A: Clinical trial results with anithrombin III in sepsis. Grit. Care Med. (2000) 28(9 Suppl.):538–543.
- SMITH D: Meeting Report: 13th Annual Congress of the European Society of Intensive Care Medicine, Rome, Italy, 1-4 October 2000 Grit. Care (2000) 4:347–351.
- OPAL SM, PALARDY JE, PAREJO NA, CREASEY AA: The activity of tissue pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial sepsis. Grit. Care Med. (2001) 29:13–17.
- DE JONGE E, DEKKERS PEP, CREASEYAA et al.: Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood (2000) 95:1124–1129.
- TAYLOR FB JR, CHANG A, EAMON CT et al.: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in baboons. J. Chi]. Invest (1987) 79:918–925.
- BERNARD GR, VINCENT JL, LATERRE PF etal.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl. J. Med. (2001) 344:699–709.
- MAY RD, HAWKSWOOD E, POWLING MJ: Superior efficacy of low molecular weight thrombin inhibitors in a novel in vitro model of clot bound thrombin. Blood (1994) 5:943–949.
- ERIKSSON M, LARSSON A, SALDEEN T, MATTSSON C: Melagatran, a low molecular weight thrombin inihibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig. Thromb. Haemost. (1998) 80:1022–1026.
- ERIKSSON M, SALDEEN T, MATTSSON C, LARSSON A: Effects of melagatran, an inihibitor of thrombin, on fibrin deposits, haemodynamics and platelet count in endotoxaemic pigs. Acta Anesthesia. Land. (2000) 44:24–31.
- VOLANAKIS JE: Overview of the complement system. In: The Human Complement System in Health and Disease, Volanakis JE, Frank MM, (Eds.), Marcel Dekker, Inc., New York (1998):9.
- ASGHAR SS, PASCH MC: Therapeutic inhibition of the complement system. Front Biosci (2000) 5:E63–E81.
- HACK, OLGIVIE, EISELE et al: Cl-inhibitor substitution therapy in septic shock and in vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med. (1993) 19:S19–S28.
- NORNBERGER, MICHELMANN, PETRIK etal.: Acivity of Cl-esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation. Ann. Hematology (1993) 67:17–21.
- ZEERLEDER S, CALIEZI CH, REDONDO M et al.: Activation of the plasmatic cascade in sepsis: Role of Cl-inhibitor. Schweiz Med. Wochenschr (1999) 129:1410–1417.
- HUBER-LANG MS, SARMA JV, MCGUIRE SR etal.: Protective effects of anti-05a peptide antibodies in experimental sepsis. FASEB J. (2001) 15:568–570.
- LEAVER HA, QU JM, SMITH G et al: Endotoxin releases platelet-activating factor from human monocytes in vitro. Immunopharmacology (1990) 20:105–113.
- MYERS AK, ROBEY JW, PRICE RIVI: Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice. Br j Pharmacol (1990) 99:499–502.
- SERHAN CN, HAEGGSTROM JZ, LESLIE CC: Lipid mediator networks in cell signaling: Update and impact of cytokines. FASEB J. (1996) 10:1147–1158.
- MAEIR RV, HAHNEL GB, FLETCHER JR: Platelet-activating factor augments tumor necrosis factor and procoagulant activity. J. Surg. Res. (1992) 52:258–264.
- SZABO C, WU CC, MITCHELL JA et al: Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ. Res. (1993) 73:991–999.
- HERBERTSON MJ, WERNER HA, WALLEY KR: Platelet-activating factor antagonism improves ventricular contractility in endotoxemia. Grit. Care Med. (1997) 259:221–226.
- SIEBECK M, WEIPERT J, KESER C et al.: A triazolodiazepine platelet-activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxic shock in swine. J. Trauma (1991) 31:942–950.
- ONO S, MOCHIZUKI H, TAMAKUMA S: A clinical study on the significance of platelet-activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery. Am. J. Surg. (1996) 171:409–415.
- GRAHAM RIVI, STEPHENS CJ, SILVESTER W et al: Plasma degredation of platelet-activating factor in severely ill patients with clinical sepsis. Grit. Care Med. (1994) 22:204–212.
- FLETCHER JR, DISIMONE AG, EARNEST MA: Platelet-activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia. Ann. Surg. (1990) 211:312–316.
- KRUSE-ELLIOT KT, ALBERT DH, SUMMERS JB et al: Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist. Shock (1996) 5:265–273.
- NEWALL CA, ANDERSON LA, PHILLIPSON JD: Ginkgo Biloba monograph. In: Herbal Medicines: A Guide for Health-Care Professionals, Pharmaceutical Press, London (1996):138.
- KOLTAI M, OSFORD D, GUINOT P et al.: Platelet activating factor: A review of its effects antagonists and possible future applications (Parts I and II). Drugs (1991) 42:9-29, 174–204.
- DHAINAUT JFA, TENAILLON A, LE TULZO Y etal.: Platelet-activating factor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Grit. Care Med. (1994) 22:1720–1728.
- DHAINAUT JFA, TENAILLON A, HEMMER M et al.: Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis. A Phase III, randomized, double-blind, placebo-controlled, multicenter trial. Grit. Care Med. (1998) 26:1936–1971.
- SUPUTTAMONGKOL Y, INTARANONGPAI S, SMITH MD et al: A double-blind placebo-controlled study of an infuxion of lexipafant (platelet-activating factor antagonist) in patients with severe sepsis. Antimicrob. Agents Chemother. (2000) 44:693–696.
- VINCENT JL, SPAPEN H, BAKKER J et al.: Phase II multicenter clinical study of the platelet-activating factor resceptor antagonist BB-882 in the treatment of sepsis. Grit. Care Med. (2000) 28:638–642.
- TAGGART DP: Effects of a platelet-activating factor antagonist on lung injury and ventilation after cardiac operation.
- JOHNSON CD, KINGSNORTH AN, IMRIE CW et al.: Double blind, randomized, placebo-controlled study of a platelet-activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Cut (2001) 48:62–69.
- TJOELKER LW, STAFFORINI DM: Platelet-activating factor acetylhydrolases in health and disease. Biochimica et Biophysica Acta (2000) 1488:102–123.
- HENDERSON WR, LU JY, POOLE KM etal.: Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model. ..J. Immunol (2000) 164:3360–3367.
- HENIG NR, AITKEN ML, LIU MC et al.:Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. Am. Resp. Grit. Care Med. (2000) 162:523–527.
- SHERMAN S, LEHMAN GA, GEENEN Jet al.: Evaluation of recombinant human platelet-activating factor acetylhydrolase (rPAF-AH) for reducing the incidence and severity of post-ERCP acute pancreatitis. Gastrointestinal Endoscopy (2000) 51:3346–3346.
- KUMAR A, KRIEGER A, SYMEONEIDES S, PARILLO J: Myocardial dysfunction in septic shock, part II. Role of cytokines and nitric oxide. J. Cardiovasc. Thoracic Ariesth (In Press).
- LAMAS S, MICHEL T: Molecular and biological features of nitric oxide synthase isofroms. In: Nitric Oxide and the Lung. Zapol W, Bloch KD, eds. Marcel Dekker, New York (1996):59
- LAMAS S, MICHEL T: Endothelium-derived nitric oxide and control of vascular tone. In: Principles of Molecular Medicine. Jameson JL (Ed.), Humana Press, New Jersy, USA (1998):141.
- WHITTLE B: Nitric oxide in physiology and pathology. Histochem. J. (1995) 27:727–737.
- DUSTING G: Nitric oxide in cardiovascular disorders. J. Vase. Res. (1995) 32:143–161.
- SZABO C: The pathophysiological role ofperoxynitrite in shock, inflammation and ischemia-reperfusion injury. Shock (1996) 6:79–88.
- GROVER R, BAKKER J, MCLUCKIE A et al.: The nitric oxide synthase inhibitor, 546C88, promotes the resolution of shock in patients with severe sepsis. Grit. Care Med. (1998) 26\(Suppl. 1):29A (Abstract).
- BAKKER J, WEG, J, ZACCARDELLI D et al.: Multi-center, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor, 546C88, in patients with septic shock: Effects on cardiovascular function. (abstract) Grit. Care Med. (1998) 26(Suppl. I):63A.
- GROVER R, ZACCARDELLI D, COLICE G et al: An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Grit. Care Med. (1999) 27:913–922.
- GROVER R, LOPEZ A, LORENTE J et al.: Multi-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect in survival in patients with septic shock. Grit. Care Med. (1999) 27:33A.
- KUMAR A, OSMAN J: Septic myocardial depression: No 'no' to NO? (editorial) Grit. Care Med. (2001) 29:202–203.
- THIEMERMANN C, RUETTEN H, WU C et al.: The multiple organ dysfunction syndrome caused by endotoxin in the rat: Attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J. Pharmacol (1995) 116:2845–2851.
- FATEHI-HASSANABAD Z, BURNS H, AUGHEY E et al.: Effects of L-canavanine, an inhibitor of inducible nitric oxide synthase on endotoxin mediated shock in rats. Ain. J. Physiol (1996) 6:194–200.
- BUNE A, BRAND M, HEALES S et al: Inihbition of tetrahydrobiopterin synthesis reduces in vitro nitric oxide production in experimental endotoxic shock. Biochein. Biophys. Res. Comm 220:13–19.
- FRICKER SP: Nitric oxide scavengers as a therapeutic approach to nitric oxide mediated disease. Expert Opin. Investig. Drugs (1999) 8:1209–1222.
- SIELENKAMPER AW, CHIN-YEE IH, MARTIN CM et al.: Diaspirin crosslinked hemoglobin improves systemic oxygen uptake in oxygen supply-dependent septic rats. Am J. Respir Grit. Care Med. (1997) 156:1066–1072.
- WINSLOW RM, GONZALES A, GONZALES ML et al: Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model. I Appl. Physiol (1998) 85:993–1003.
- CRETEUR J, VINCENT JL: Hemoglobin solutions: An 'all-in-one' therapeutic strategy in sepsis? (editorial) Grit. Care Med. (2000) 28:894–896.
- SLOAN EP, KOENISBERG M, GENS D et al: Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhage. JAMA (1999) 282:1857–1864.
- BONE HG, FISCHER SR, SCHENARTS PJ et al.: Continuous infusion of pyridoxilated hemoglobin polyoxyethylene conjugate in hyperdynamic septic sheep. Shock (1998) 10:69–76.
- MOLINA L, STUDENBERG S, WOLBERG G etal.: Efficacy of treatment with iron (III) complex of diethylenetriamine pentaacetic acid in mice and primates inoculated with live lethal dose 100 Escherechia coil. j Gift]. Invest. (1996) 98:192–198.
- GREENBERG S, XIE J, ZATARAIN JM et al.: Hydroxycobalamin prevents and reverses endotoxin-induced hypotension and mortality in rodents: Role of nitric oxide. J. Pharmacol Exp. Ther. (1995) 273:257–265.
- FRICKER SP: Ruthenium, nitric oxide and disease. Plainum Metals Rev (1995) 39:150–159.
- DENNER L: Caspases in apoptotic death. Expert Opin. Investig. Drugs (1999) 8:37–50.
- CASTELINO DJ, MCNAIR P, KAY TW: Lymphocytopenia in a hospital population - what does it signify? Aust. NZ J. Med. (1997) 27:170–174.
- HOTCHKISS RS, SWANSON PE, FREEMAN BD et al.: Apoptotic cell death in patients with sepsis, shock and multiple organ dysfunction. Grit. Care Med. (1999) 27:1230–1251.
- TINSLEY, KW, CHENG SL, BUCHMAN TG et al: Caspase-2,-3,-6, and -9 but not caspase-1, are activated in sepsis-induced thymocyte apoptosis. Shock (2000) 13:1–7.
- OBERHOLZER C, OBERHOLZER A, CLARE-SALZLER M, MOLDAWER L: Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J. (2001) 15:879–892.
- AYALA A, CHUNG CS, SONG GY, CHAUDRY IH: I1-10 mediation of activation-induced th(l)cell apoptosis and lymphoid dysfunction in polymicrobial sepsis. Cytokine (2001) 14:37–48.
- BRAUN JS, NOVAK R, HERZOG KH et al.: Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat. Med. (1999) 5:298–302.
- HOTCHKISS RS, TINSLEY KW, SWANSON PE et al.: prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad Sci (1999) 96: 14541–14546.
Websites
- www.anesthesiologyonline.com MCGRATH B: Perioperative management of sepsis and septic shock. Anesthesiology Online (2000)